| Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals S Perez, A Kaspi, T Domovitz, A Davidovich, A Lavi-Itzkovitz, T Meirson, ... PLoS genetics 15 (6), e1008181, 2019 | 129 | 2019 |
| Oral inflammation promotes oral squamous cell carcinoma invasion C Goertzen, H Mahdi, C Laliberte, T Meirson, D Eymael, H Gil-Henn, ... Oncotarget 9 (49), 29047, 2018 | 103 | 2018 |
| Targeting invadopodia for blocking breast cancer metastasis T Meirson, H Gil-Henn Drug Resistance Updates 39, 1-17, 2018 | 84 | 2018 |
| Invasion and metastasis: the elusive hallmark of cancer T Meirson, H Gil-Henn, AO Samson Oncogene 39 (9), 2024-2026, 2020 | 82 | 2020 |
| Flow patterns in externally stented saphenous vein grafts and development of intimal hyperplasia T Meirson, E Orion, C Di Mario, C Webb, N Patel, KM Channon, YB Gal, ... The Journal of Thoracic and Cardiovascular Surgery 150 (4), 871-879, 2015 | 70 | 2015 |
| Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells A Genna, S Lapetina, N Lukic, S Twafra, T Meirson, VP Sharma, ... Journal of Cell Biology 217 (1), 375-395, 2018 | 56 | 2018 |
| Real world outcomes of ipilimumab and nivolumab in patients with metastatic melanoma N Asher, G Ben-Betzalel, S Lev-Ari, R Shapira-Frommer, ... Cancers 12 (8), 2329, 2020 | 51 | 2020 |
| Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre‐COVID‐19 reports A Goldman, D Bomze, R Dankner, H Hod, T Meirson, B Boursi, E Maor British Journal of Clinical Pharmacology 87 (3), 1432-1442, 2021 | 47 | 2021 |
| Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors T Meirson, A Genna, N Lukic, T Makhnii, J Alter, VP Sharma, Y Wang, ... Oncotarget 9 (31), 22158, 2018 | 38 | 2018 |
| Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma T Meirson, F Pentimalli, F Cerza, G Baglio, SG Gray, P Correale, ... JAMA Network Open 5 (3), e221490-e221490, 2022 | 34 | 2022 |
| Vesicular acetylcholine transporter defect underlies devastating congenital myasthenia syndrome A Aran, R Segel, K Kaneshige, S Gulsuner, P Renbaum, S Oliphant, ... Neurology 88 (11), 1021-1028, 2017 | 33 | 2017 |
| Ocular adverse events induced by immune checkpoint inhibitors: a comprehensive pharmacovigilance analysis D Bomze, T Meirson, O Hasan Ali, A Goldman, L Flatz, Z Habot-Wilner Ocular immunology and inflammation 30 (1), 191-197, 2022 | 31 | 2022 |
| Tumor cell density regulates matrix metalloproteinases for enhanced migration H Jayatilaka, FG Umanzor, V Shah, T Meirson, G Russo, B Starich, P Tyle, ... Oncotarget 9 (66), 32556, 2018 | 31 | 2018 |
| Structural basis of SARS-CoV-2 spike protein induced by ACE2 T Meirson, D Bomze, G Markel Bioinformatics 37 (7), 929-936, 2021 | 29 | 2021 |
| Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy A Nissani, S Lev-Ari, T Meirson, E Jacoby, N Asher, G Ben-Betzalel, ... Journal for ImmunoTherapy of Cancer 9 (5), 2021 | 28 | 2021 |
| Intracerebroventricular administration of L-arginine improves spatial memory acquisition in triple transgenic mice via reduction of oxidative stress and apoptosis G Fonar, B Polis, T Meirson, A Maltsev, E Elliott, AO Samson Translational Neuroscience 9 (1), 43-53, 2018 | 26 | 2018 |
| Hemodynamic and mechanical aspects of fenestrated endografts for treatment of abdominal aortic aneurysm I Avrahami, M Brand, T Meirson, Z Ovadia-Blechman, M Halak European Journal of Mechanics-B/Fluids 35, 85-91, 2012 | 26 | 2012 |
| Survival-inferred fragility index of phase 3 clinical trials evaluating immune checkpoint inhibitors D Bomze, N Asher, OH Ali, L Flatz, D Azoulay, G Markel, T Meirson JAMA network open 3 (10), e2017675-e2017675, 2020 | 25 | 2020 |
| Hepatitis C virus enhances the invasiveness of hepatocellular carcinoma via EGFR-mediated invadopodia formation and activation L Ninio, A Nissani, T Meirson, T Domovitz, A Genna, S Twafra, ... Cells 8 (11), 1395, 2019 | 24 | 2019 |
| Safety of BRAF+ MEK inhibitor combinations: severe adverse event evaluation T Meirson, N Asher, D Bomze, G Markel Cancers 12 (6), 1650, 2020 | 22 | 2020 |
